How often is TB-500 dosed?

No established human dosing protocol

TB-500 is not FDA-approved and has no completed human dosing trial establishing a frequency. The loading-then-maintenance regimen repeated across the research community is convention, loosely attributed to early clinical trials whose doses were never published. This page reports that state rather than presenting the convention as an answer.

What the cited literature actually studied

The cited TB-500 studies examined mechanism, cell migration, and wound-healing outcomes — not a dosing schedule. The multi-day half-life that is offered as the rationale for infrequent dosing is an estimate from animal pharmacokinetics, not a human-trial figure. No cited study reports a frequency or dose amount for research use.

For how TB-500 and BPC-157 compare as research peptides, see the BPC-157 vs TB-500 comparison.

• No human clinical trial has established a dosing frequency.
• The circulating twice-weekly/loading-maintenance figures are community convention.
• The cited studies cover mechanism and wound healing, not a schedule.
• The multi-day half-life is an animal-study estimate.